On May 29, 2025, Zevra Therapeutics, Inc. held its annual meeting where Wendy Dixon, Ph.D. and Tamara A. Favorito were elected as directors, and Ernst & Young LLP was ratified as the accounting firm for 2025. 81.4% of shares were represented at the meeting.